Ranolazine Therapy in Cardiac Arrhythmias

Ranolazine is an antianginal medication originally granted approval by the U.S. Food and Drug Administration for therapeutic use in 2006. Since its introduction into the U.S. market, there have been multiple trials and clinical case reports that demonstrate ranolazine may be effective in the prevent...

Full description

Saved in:
Bibliographic Details
Published in:Pacing and clinical electrophysiology 2016-09, Vol.39 (9), p.1006-1015
Main Authors: PULFORD, BRIAN R., KLUGER, JEFFREY
Format: Article
Language:English
Subjects:
Anti-Arrhythmia Agents - administration & dosage
Anti-Arrhythmia Agents - adverse effects
Arrhythmias, Cardiac - diagnosis
Arrhythmias, Cardiac - drug therapy
Arrhythmias, Cardiac - prevention & control
atrial fibrillation
clinical trials
data analysis
Dose-Response Relationship, Drug
Drug Administration Schedule
Evidence-Based Medicine
Humans
pharmacology
Ranolazine - administration & dosage
Ranolazine - adverse effects
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ranolazine is an antianginal medication originally granted approval by the U.S. Food and Drug Administration for therapeutic use in 2006. Since its introduction into the U.S. market, there have been multiple trials and clinical case reports that demonstrate ranolazine may be effective in the prevention and treatment of both atrial and ventricular arrhythmias, including postoperative atrial fibrillation following coronary artery bypass graft (CABG) surgery. More recently, the combination of dronedarone with ranolazine has demonstrated in initial studies to have a synergistic effect in the reduction of burden of atrial fibrillation. This article will review the basic pharmacology of ranolazine, the studies demonstrating use of ranolazine in atrial and ventricular arrhythmias, the limitations to the use of ranolazine as antiarrhythmic therapy, and explore the synergistic effect with other agents in the suppression of arrhythmias.
ISSN:0147-8389
1540-8159
DOI:10.1111/pace.12905